The Cooper Companies, Inc. (NASDAQ:COO) Stock Has Average Target Price of $71.47 According to Brokerages

The Cooper Companies, Inc. (NASDAQ:COO) has been given a consensus rating of “Hold” by the nineteen analysts that are currently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating and five have issued a buy rating on the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $71.47.

COO has been the topic of a number of research reports. BNP Paribas Exane lowered their price target on Cooper Companies from $95.00 to $92.00 and set an “outperform” rating on the stock in a report on Monday, June 8th. UBS Group decreased their price objective on Cooper Companies from $75.00 to $66.00 and set a “neutral” rating for the company in a research report on Thursday, September 10th. Stifel Nicolaus set a $70.00 target price on Cooper Companies and gave the company a “buy” rating in a research note on Thursday, September 10th. JPMorgan Chase & Co. dropped their target price on Cooper Companies from $71.00 to $58.00 and set a “neutral” rating on the stock in a report on Thursday, September 10th. Finally, KeyCorp restated a “sector weight” rating on shares of Cooper Companies in a research note on Friday, June 5th.

Cooper Companies Stock Down 0.9%

COO opened at $56.91 on Friday. The business’s 50-day simple moving average is $66.95 and its 200-day simple moving average is $67.20. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.73 and a current ratio of 1.22. Cooper Companies has a one year low of $51.01 and a one year high of $89.83. The stock has a market capitalization of $10.82 billion, a P/E ratio of 19.42, a price-to-earnings-growth ratio of 2.34 and a beta of 0.83.

Cooper Companies (NASDAQ:COO) last announced its earnings results on Wednesday, September 9th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.12 by $0.03. Cooper Companies had a return on equity of 10.90% and a net margin of 13.46%.The firm had revenue of $1.07 billion during the quarter, compared to analysts’ expectations of $1.10 billion. During the same period in the prior year, the firm earned $0.49 EPS. The business’s revenue was up .5% on a year-over-year basis. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. Analysts anticipate that Cooper Companies will post 4.53 EPS for the current year.

Cooper Companies declared that its board has authorized a share repurchase plan on Wednesday, September 9th that permits the company to repurchase $3.00 billion in outstanding shares. This repurchase authorization permits the medical device company to repurchase up to 22.7% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board of directors believes its stock is undervalued.

Key Cooper Companies News

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Director Kurzius purchased 10,000 COO shares at $54.93 each, investing approximately $549,300. The purchase represented 47% of the director’s prior equity stake and may signal confidence that the stock is undervalued. Cooper Companies Director Kurzius Buys $549,300 in Shares
• Neutral Sentiment: Several law firms, including Rosen and Pomerantz, are soliciting investors in connection with investigations into whether Cooper Companies issued materially misleading information. These announcements do not establish wrongdoing or financial liability, but they add uncertainty and could lead to future legal costs or claims. Rosen Securities Class Action Investigation
• Negative Sentiment: Zacks Research lowered its EPS forecasts across multiple periods, including Q4 2026 to $1.07 from $1.19, FY2026 to $4.53 from $4.61, FY2027 to $4.70 from $4.91, and FY2028 to $5.19 from $5.42. Zacks also maintained a “Strong Sell” rating, reinforcing concerns about slowing earnings momentum.
• Negative Sentiment: The company’s latest results revealed U.S. channel inventory destocking and other unfavorable surprises. The disclosures triggered a major selloff on September 10, eliminating more than $1.7 billion in market value and remaining the primary driver of weakness in COO shares. Cooper Companies Scrutinized Over U.S. Channel Inventory Reductions

Insider Buying and Selling at Cooper Companies

In other news, Director Walter Rosebrough, Jr. acquired 7,000 shares of the business’s stock in a transaction on Friday, September 11th. The stock was bought at an average price of $54.11 per share, for a total transaction of $378,770.00. Following the transaction, the director owned 17,000 shares in the company, valued at $919,870. This represents a 70.00% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Paul Keel bought 4,701 shares of Cooper Companies stock in a transaction dated Friday, September 11th. The stock was purchased at an average price of $53.18 per share, with a total value of $249,999.18. Following the purchase, the director directly owned 4,701 shares in the company, valued at approximately $249,999.18. This trade represents a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders have bought 34,701 shares of company stock valued at $1,880,039. 2.08% of the stock is owned by company insiders.

Hedge Funds Weigh In On Cooper Companies

Several hedge funds have recently bought and sold shares of the stock. Envestnet Portfolio Solutions Inc. raised its stake in Cooper Companies by 112.8% in the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 15,784 shares of the medical device company’s stock valued at $1,132,000 after purchasing an additional 8,366 shares during the last quarter. HBK Investments L P acquired a new stake in shares of Cooper Companies during the 2nd quarter worth about $31,666,000. Sequoia Financial Advisors LLC grew its holdings in shares of Cooper Companies by 290.4% during the second quarter. Sequoia Financial Advisors LLC now owns 34,286 shares of the medical device company’s stock worth $2,459,000 after buying an additional 25,504 shares in the last quarter. Tidal Investments LLC raised its position in shares of Cooper Companies by 281.4% in the second quarter. Tidal Investments LLC now owns 82,903 shares of the medical device company’s stock valued at $5,945,000 after buying an additional 61,165 shares during the last quarter. Finally, National Pension Service raised its position in shares of Cooper Companies by 9,314.0% in the second quarter. National Pension Service now owns 526,149 shares of the medical device company’s stock valued at $37,730,000 after buying an additional 520,560 shares during the last quarter. Hedge funds and other institutional investors own 24.39% of the company’s stock.

Cooper Companies Company Profile

CooperCompanies (NASDAQ: COO) is a global medical device company focused on improving vision and advancing women’s health. Its operations are organized primarily through CooperVision and CooperSurgical, which develop, manufacture and distribute products for eye care, fertility and other areas of reproductive health.

CooperVision offers a broad range of contact lenses, including lenses for nearsightedness, farsightedness, astigmatism and presbyopia. Its portfolio includes daily disposable, reusable and specialty lenses, as well as products designed to address the progression of myopia in children and adolescents.